BioGaia AB Year-end report 2010
(Thomson Reuters ONE) -
BioGaia Year-end report 2010
2010
- Net sales reached SEK 236.0 million (203.5), an increase of SEK 32.5 million
(16%). Excluding foreign exchange effects, the increase in net sales was 27%1).
- Operating profit was SEK 56.3 million (47.7), an improvement of SEK 8.6
million (18%). Excluding foreign exchange effects, operating profit rose by
51%1).
- Profit before tax was SEK 69.7 million (53.1), an increase of SEK 16.6 million
(31%).
- The year's profit after tax was SEK 47.2 million (36.0), an improvement of SEK
11.2 million (31%).
- Earnings per share amounted to SEK 2.74 (2.11).
- The year's cash flow from operating activities before changes in working
capital was SEK 66.0 million (52.6). Total cash flow for the year was SEK 47.5
million (42.5). Dividends of SEK 25.8 million (6.9) were paid during the year at
the same time that the company raised SEK 4.9 million from the new shares issued
in connection with the redemption of warrants. Cash and cash equivalents at 31
December 2010 amounted to SEK 146.9 million (100.3). At the beginning of 2011
corporate tax of SEK 18.4 million attributable to 2010 was paid.
- The Board proposes that the upcoming AGM approve an ordinary dividend of SEK
0.92 and an extraordinary dividend of SEK 1.08, for a total dividend of SEK
2.00 per share.
Fourth quarter, 1 October - 31 December 2010
- Net sales amounted to SEK 62.8 million (52.3), an increase of SEK 10.5 million
(20%). Excluding foreign exchange effects, the increase in net sales was 34%.1)
- Operating profit was SEK 16.2 million (11.4), an improvement of SEK 4.8
million (42%). Excluding foreign exchange effects, operating profit rose by
88%. 1)
- Profit before tax was SEK 18.6 million (10.5), an increase of SEK 8.1 million
(77%).
- Profit after tax for the period was SEK 12.9 million (6.8), an improvement of
SEK 6.1 million (90%).
Key events in the fourth quarter of 2010
- Publication of study showing that Lactobacillus reuteri Protectis is effective
in treatment of periodontitis.
- New study published: Lactobacillus reuteri Protectis reduced regurgitation and
improved stomach emptying in infants.
Key events after the end of the financial year
- BioGaia signs agreement for its new Oral Rehydration Solution product for
Greece
- BioGaia's 50%-owned company TwoPac invests in a new facility in Eslöv.
"On the whole, we thus had a very strong development during 2010 and are
building value by investing further in clinical research, product development
and the BioGaia brand," says Peter Rothschild, President of BioGaia.
1) Most of the company's sales are denominated in foreign currency, primarily
EUR. With unchanged exchange rates, net sales would have been SEK 23.0 million
higher and operating profit would have been SEK 15.7 million higher for the
year.
BioGaia publishes this information in accordance with the Swedish Securities
Markets Act. The information was published on February 11, 2011, at 08:00 AM
CET.
Year-end report 2010:
http://hugin.info/86913/R/1487951/423420.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioGaia AB via Thomson Reuters ONE
[HUG#1487951]
Unternehmensinformation / Kurzprofil:
Datum: 11.02.2011 - 07:59 Uhr
Sprache: Deutsch
News-ID 51362
Anzahl Zeichen: 4084
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioGaia AB Year-end report 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
BioGaia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
